EMA Authorised: Neofordex (dexamethasone) — THERAVIA

View source ↗

Summary

The European Medicines Agency has authorised Neofordex, a dexamethasone product from THERAVIA, for use in the treatment of multiple myeloma in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Neofordex (dexamethasone)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: THERAVIA. Decision date: 03/10/2024